Evidence map›Paper›PMID 18425903›Full record

SynthesisThe Cochrane database of systematic reviews2008

Danshen (Chinese medicinal herb) preparations for acute myocardial infarction.

Taixiang Wu, Juan Ni, Jiafu Wu

Open access · greenAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in The Cochrane database of systematic reviews, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 2 pooled it
7.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 44 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Cochrane systematic reviews on traditional Chinese medicine: What matters-the quantity or quality of evidence?Phytomedicine : international journal of phytotherapy and phytopharmacology · 2022
    Article
  7. Observational
  8. Review
  9. Frontiers in pharmacology · 2019
    Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Taixiang WuWest China Hospital, Sichuan University, Chinese Cochrane Centre, Chinese EBM Centre, No. 37, Guo Xue Xiang, Chengdu, Sichuan, China, 610041. txwutx@hotmail.com
Juan Ni
Jiafu Wu
West China Hospital of Sichuan University · CNSichuan University · CN

Funding

Cochrane Complementary Medicine Field: Resource for ResearchR24AT001293 · NCCIH · UNIVERSITY OF MARYLAND BALTIMORE · PI BERMAN, BRIAN M, WIELAND, LISA SUSAN · 2003 to 2022
$9.4M
NCCIH NIH HHS R24 AT001293
6 · The paper itself

Abstract

backgroundAcute myocardial infarction (AMI) is the most important cause of morbidity from ischaemic heart disease, and is among the leading causes of death in the western world. Danshen, a Chinese herbal medicine, is widely used in China for treatment of several diseases, including AMI.

objectivesTo assess the effects (both benefits and harms) of danshen preparations for AMI. SEARCH STRATEGY: We searched the Cochrane Central Register of Controlled Trials (CENTRAL) on The Cochrane Library (issue 4, 2006), MEDLINE (1966-2006), EMBASE (1980-2006), and the Chinese Biomedical Database (CBM) (1982-2006). We also handsearched 75 Chinese medical journals. SELECTION CRITERIA: Randomised controlled trials (RCTs) lasting at least 7 days were sought. Since it seemed evident that few RCTs were available, we also considered other controlled studies. DATA COLLECTION AND ANALYSIS: Eligibility and trial quality were assessed by three reviewers. MAIN

resultsSix studies comprised of 2368 participants were included. Only one trial was judged to be a genuine RCT and showed no statistically significant difference in reduction of total mortality (Peto OR 0.55, 95% CI 0.23 to 1.32), but a quasi-RCT reported a reduced total mortality (Peto OR 0.42, 95% CI 0.23 to 0.77). Pooling these trials yielded an approximate halving of mortality in those patients treated with danshen preparations plus usual care compared with usual care alone (Peto OR 0.46, 95% CI 0.28 to 0.75). AUTHORS'

conclusionsThe evidence to support use of danshen preparations is too weak to make any judgement about its effects. Evidence from RCTs is insufficient and of low quality. The safety of danshen preparations is unproven, although some adverse events have been reported. More evidence from high quality trials is needed to support the clinical use of danshen preparations.

Indexed as

PhytotherapySalvia miltiorrhizaDrugs, Chinese HerbalHumansMyocardial InfarctionPhenanthrolinesRandomized Controlled Trials as Topicdan-shen root extractDrugs, Chinese HerbalPhenanthrolines

Identifiers

PMID18425903
PMCPMC8406986
OpenAlexW1674275210

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.